Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
NCT ID NCT07659379
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of a parent gotistobart trial. The study does not test a new treatment but monitors ongoing effects and outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gotistobart (a humanized anti-CTLA4 antibody)
What this could lead to
If successful, this study could confirm that gotistobart is safe and effective for long-term use in advanced solid tumors, potentially offering a new treatment option.
What could go wrong
This is a small extension study (20 participants) focused on long-term follow-up, not a new treatment test. Results may not apply to all patients, and side effects remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.